In HIV patients with belly fat who responded to tesamorelin, thicker subcutaneous fat (on CT scans) was linked to higher adiponectin levels, which is beneficial for metabolic health.

Scientific Claim

In people living with HIV with central adiposity who responded to tesamorelin treatment, increases in subcutaneous adipose tissue density were positively correlated with increases in adiponectin levels (r=0.18, p=0.02) after adjusting for subcutaneous fat area change.

Original Statement

“Adiponectin (μg/mL) 0.18 0.02”

From study:Tesamorelin improves fat quality independent of changes in fat quantity

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study design supports correlational claims, and the language 'positively correlated' accurately reflects the statistical relationship observed.

Evidence from Studies

Supporting (0)

No supporting evidence found

Contradicting (1)

Tesamorelin improves fat quality independent of changes in fat quantity

Randomized Controlled Trial

Human

The study shows that the drug improves fat quality by making it denser, but it never measured or mentioned the hormone adiponectin, so we can't tell if the claim about the link between fat density and this hormone is true.

Source Study

Tesamorelin improves fat quality independent of changes in fat quantity

Score: 66

DOI: 10.1097/qad.0000000000002897

Similar Assertions

For HIV patients with belly fat who responded to tesamorelin, denser subcutaneous fat (on CT scans) was linked to less subcutaneous fat area, showing that fat quality and quantity are related.

96%

When HIV patients with belly fat responded to tesamorelin, thicker visceral fat (as seen on CT scans) was linked to higher levels of adiponectin, a hormone that helps regulate metabolism.

96%

Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher levels of the metabolism-regulating hormone adiponectin, suggesting improved fat function.

96%

When HIV patients on tesamorelin had denser belly fat, their bodies also produced more adiponectin, a hormone that helps regulate metabolism, showing a link between fat quality and metabolic health.

92%

For HIV patients with belly fat who responded to tesamorelin, higher subcutaneous fat density (on CT scans) was linked to lower total cholesterol levels, which is good for heart health.

92%